Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease and other neurodegenerative diseases. The company's therapeutic, AMX0035, targets the neuroinflammation and nerve cell death that characterize these diseases. AMX0035 is a proprietary combination of existing compounds that act synergistically to prevent cell death and neurotoxic inflammation in multiple preclinical models.